Anna Nordenskjöld
Research Subjects
Anna Nordenskjöld has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Olle Stål
Department of Biomedical and Clinical Sciences and Department of Oncology, Linköping University , Linköping
4 shared publicationsTommy Fornander
Department of Oncology and Pathology, Karolinska Institutet and University Hospital , Stockholm
4 shared publicationsBo Nordenskjöld
Department of Biomedical and Clinical Sciences and Department of Oncology Linköping University Linköping Sweden
3 shared publications- Annelie Johansson
Department of Oncology and Pathology, Karolinska Institutet and University Hospital , Stockholm
2 shared publications Arne Wallgren
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, 413 45, Gothenburg, Sweden
2 shared publicationsHenrik Lindman
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
2 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (7) , 1248-1256
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up
Background: Patients with estrogen receptor–positive breast cancer have a substantial late risk of distant recurrence, but the long-term subtype-specific tamoxifen benefit remains poorly understood. Methods: A secondary analysis of the Stockholm Tamoxifen randomized trials (1976-1997, n = 3930) with 20-year follow-up was conducted. Formalin-fixed, paraffin-embedded blocks were available for 2250 patients. A total of 952 patients with estrogen receptor–positive and HER2-negative tumors, classified as luminal A (n = 688) and luminal B (n = 264) using Agilent microarrays, were analyzed. Patients were randomly assigned to at least 2 years of tamoxifen therapy or no endocrine therapy. Distant recurrence-free interval was assessed by Kaplan–Meier analysis and multivariable Cox proportional hazards regression. Results: Patients with luminal A tumors had low early risk and modest early benefit from tamoxifen therapy (5-year distant recurrence-free interval treated vs control: 93% vs 89%; absolute difference = 4%) that increased over the 20-year follow-up (20-year distant recurrence-free interval: 76% vs 66%; absolute difference = 10%), highlighting long-term benefit. In contrast, patients with luminal B tumors had larger early risk and treatment benefit (5-year distant recurrence-free interval: 72% vs 57%; absolute difference = 15%), which remained stable over time (20-year distant recurrence-free interval: 55% vs 37%; absolute difference = 18%). Multivariable analyses showed that luminal patients benefited from tamoxifen therapy (luminal A: adjusted hazard ratio [HR] = 0.57, 95% confidence interval [CI] = 0.42 to 0.78; luminal B: adjusted HR = 0.68, 95% CI = 0.46 to 0.99). Patients with favorable tumor characteristics benefited regardless of luminal subtype. Conclusions: Tamoxifen reduces the long-term risk of distant recurrence in luminal A and B tumors, although timing of benefit varies by subtype. Even after treatment, patients with luminal tumors have a substantial late risk, highlighting the need for long-term follow-up. Clinical Trial Registration: The trial center for the Stockholm Tamoxifen trials was the Regional Cancer Center Stockholm-Gotland, in Stockholm, Sweden. The start of the Stockholm Tamoxifen trials in 1976 was before the custom of trial registration started in Sweden, therefore no trial number is available.
- 19 February 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (7) , 1248-1256
Open AccessTamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up
Background: Patients with estrogen receptor–positive breast cancer have a substantial late risk of distant recurrence, but the long-term subtype-specific tamoxifen benefit remains poorly understood. Methods: A secondary analysis of the Stockholm Tamoxifen randomized trials (1976-1997, n = 3930) with 20-year follow-up was conducted. Formalin-fixed, paraffin-embedded blocks were available for 2250 patients. A total of 952 patients with estrogen receptor–positive and HER2-negative tumors, classified as luminal A (n = 688) and luminal B (n = 264) using Agilent microarrays, were analyzed. Patients were randomly assigned to at least 2 years of tamoxifen therapy or no endocrine therapy. Distant recurrence-free interval was assessed by Kaplan–Meier analysis and multivariable Cox proportional hazards regression. Results: Patients with luminal A tumors had low early risk and modest early benefit from tamoxifen therapy (5-year distant recurrence-free interval treated vs control: 93% vs 89%; absolute difference = 4%) that increased over the 20-year follow-up (20-year distant recurrence-free interval: 76% vs 66%; absolute difference = 10%), highlighting long-term benefit. In contrast, patients with luminal B tumors had larger early risk and treatment benefit (5-year distant recurrence-free interval: 72% vs 57%; absolute difference = 15%), which remained stable over time (20-year distant recurrence-free interval: 55% vs 37%; absolute difference = 18%). Multivariable analyses showed that luminal patients benefited from tamoxifen therapy (luminal A: adjusted hazard ratio [HR] = 0.57, 95% confidence interval [CI] = 0.42 to 0.78; luminal B: adjusted HR = 0.68, 95% CI = 0.46 to 0.99). Patients with favorable tumor characteristics benefited regardless of luminal subtype. Conclusions: Tamoxifen reduces the long-term risk of distant recurrence in luminal A and B tumors, although timing of benefit varies by subtype. Even after treatment, patients with luminal tumors have a substantial late risk, highlighting the need for long-term follow-up. Clinical Trial Registration: The trial center for the Stockholm Tamoxifen trials was the Regional Cancer Center Stockholm-Gotland, in Stockholm, Sweden. The start of the Stockholm Tamoxifen trials in 1976 was before the custom of trial registration started in Sweden, therefore no trial number is available.
- Open Access
- 24 October 2025
- Published by Wiley in International Journal of Cancer
- Vol. 158 (4) , 1106-1115
Progesterone receptor ( PR ) intra‐tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial
Premenopausal breast cancer patients have an increased risk of distant recurrence, but their long‐term risk remains unclear. Notably, over 90% of estrogen receptor (ER) positive tumors in premenopausal patients are also progesterone receptor (PR) positive, compared to 70% in postmenopausal patients. We aimed to determine whether PR intra‐tumor heterogeneity influences long‐term risk of distant recurrence and endocrine therapy benefit in premenopausal breast cancer patients. We conducted a secondary analysis of the Stockholm tamoxifen (STO‐5) randomized controlled trial (1990–1997) with 20‐year complete follow‐up, including 924 premenopausal women with operable breast cancer in Stockholm, Sweden. Patients were randomized to 2 years of adjuvant endocrine therapy or control, with lymph node‐positive patients receiving standard chemotherapy (CMF). Tumor blocks were available for 731 patients. PR intra‐tumor heterogeneity was assessed by measuring variation in PR immunohistochemical staining intensity in whole tumor slides and was categorized as high or low for 520 ER‐positive/PR‐positive patients. Distant recurrence‐free interval (DRFI) by PR heterogeneity was analyzed using Kaplan–Meier, multivariable Cox proportional‐hazards regression, and multivariable time‐varying flexible parametric modeling. We found PR intra‐tumor heterogeneity significantly impacted 20‐year DRFI (log‐rank p = .002). Patients with high intra‐tumor heterogeneity had a significantly increased risk of distant recurrence, compared to patients with low heterogeneity (hazard ratio [HR] = 1.42; 95% CI, 1.02–1.96). Similar results were observed in HER2‐negative patients. Patients with high PR heterogeneity significantly benefited from endocrine therapy (HR = 0.41; 95% CI, 0.24–0.71). These findings suggest that premenopausal patients with high PR heterogeneity have increased long‐term risk but significantly benefit from endocrine therapy.
- 24 October 2025
- Published by Wiley in International Journal of Cancer
- Vol. 158 (4) , 1106-1115
Open AccessProgesterone receptor ( PR ) intra‐tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial
Premenopausal breast cancer patients have an increased risk of distant recurrence, but their long‐term risk remains unclear. Notably, over 90% of estrogen receptor (ER) positive tumors in premenopausal patients are also progesterone receptor (PR) positive, compared to 70% in postmenopausal patients. We aimed to determine whether PR intra‐tumor heterogeneity influences long‐term risk of distant recurrence and endocrine therapy benefit in premenopausal breast cancer patients. We conducted a secondary analysis of the Stockholm tamoxifen (STO‐5) randomized controlled trial (1990–1997) with 20‐year complete follow‐up, including 924 premenopausal women with operable breast cancer in Stockholm, Sweden. Patients were randomized to 2 years of adjuvant endocrine therapy or control, with lymph node‐positive patients receiving standard chemotherapy (CMF). Tumor blocks were available for 731 patients. PR intra‐tumor heterogeneity was assessed by measuring variation in PR immunohistochemical staining intensity in whole tumor slides and was categorized as high or low for 520 ER‐positive/PR‐positive patients. Distant recurrence‐free interval (DRFI) by PR heterogeneity was analyzed using Kaplan–Meier, multivariable Cox proportional‐hazards regression, and multivariable time‐varying flexible parametric modeling. We found PR intra‐tumor heterogeneity significantly impacted 20‐year DRFI (log‐rank p = .002). Patients with high intra‐tumor heterogeneity had a significantly increased risk of distant recurrence, compared to patients with low heterogeneity (hazard ratio [HR] = 1.42; 95% CI, 1.02–1.96). Similar results were observed in HER2‐negative patients. Patients with high PR heterogeneity significantly benefited from endocrine therapy (HR = 0.41; 95% CI, 0.24–0.71). These findings suggest that premenopausal patients with high PR heterogeneity have increased long‐term risk but significantly benefit from endocrine therapy.
- Open Access
- 24 July 2023
- Published by Elsevier in The Breast
- Vol. 71, 63-68
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
- 24 July 2023
- Published by Elsevier in The Breast
- Vol. 71, 63-68
Open AccessBreast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
- Open Access
- 3 May 2023
- Published by Springer Nature in Research Square
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material and methods: We studied 30 years outcome of 4124 postmenopausal patients who were randomized to receive (totally) two or five years of adjuvant tamoxifen. Results: After 5 years of follow-up, when tamoxifen treatment was finished in both groups, until 15 years of follow-up, overall mortality (HR 0.80, 95% CI 0.72 – 0.90, p< 0.001), breast cancer mortality for all patients (HR 0.80, 95% CI 0.68 – 0.94, p= 0.006) and breast cancer mortality for patients with estrogen receptor positive disease (HR 0.67, 95% CI 0.55 – 0.83, p< 0.001) were significantly reduced in the five-year group as compared to the two-year group. After 15 years, the difference remained but did not further increase. In the five-year group, the incidence of contralateral breast cancer was gradually reduced during the entire period of observation. The incidence of lung cancer was also reduced in the five-year group. In contrast there was an increased endometrial cancer incidence in the five-year group and for those receiving 40 mg of tamoxifen this incidence was further increased. Conclusion: Three more years of tamoxifen therapy reduced the risk of breast cancer mortality. The difference was established during the first 15 years after randomization. Moreover, the incidence of contralateral breast cancer gradually decreased for 30 years. The incidence of lung cancer was reduced in the five-year group. In contrast the incidence of endometrial cancer was increased.
- 3 May 2023
- Published by Springer Nature in Research Square
Open AccessBreast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material and methods: We studied 30 years outcome of 4124 postmenopausal patients who were randomized to receive (totally) two or five years of adjuvant tamoxifen. Results: After 5 years of follow-up, when tamoxifen treatment was finished in both groups, until 15 years of follow-up, overall mortality (HR 0.80, 95% CI 0.72 – 0.90, p< 0.001), breast cancer mortality for all patients (HR 0.80, 95% CI 0.68 – 0.94, p= 0.006) and breast cancer mortality for patients with estrogen receptor positive disease (HR 0.67, 95% CI 0.55 – 0.83, p< 0.001) were significantly reduced in the five-year group as compared to the two-year group. After 15 years, the difference remained but did not further increase. In the five-year group, the incidence of contralateral breast cancer was gradually reduced during the entire period of observation. The incidence of lung cancer was also reduced in the five-year group. In contrast there was an increased endometrial cancer incidence in the five-year group and for those receiving 40 mg of tamoxifen this incidence was further increased. Conclusion: Three more years of tamoxifen therapy reduced the risk of breast cancer mortality. The difference was established during the first 15 years after randomization. Moreover, the incidence of contralateral breast cancer gradually decreased for 30 years. The incidence of lung cancer was reduced in the five-year group. In contrast the incidence of endometrial cancer was increased.